X4 Pharmaceuticals (XFOR) EBIT (2017 - 2026)
X4 Pharmaceuticals' (XFOR) quarterly EBIT came in at -$23.7 million in Q4 2025, up 33.64% YoY from -$17.7 million in Q4 2024, and up 13.85% on a QoQ basis from -$27.5 million in Q3 2025.
X4 Pharmaceuticals (XFOR) EBIT (2017 - 2026) Analysis & Trends
X4 Pharmaceuticals (XFOR) has 9 years of EBIT data on file, last reported at -$23.7 million in Q4 2025.
- Quarterly EBIT rose 33.64% year-over-year to -$23.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$86.9 million (down 138.68% YoY) and the FY2025 annual result came in at -$86.9 million, down 138.68% from the prior year.
- EBIT grew to -$23.7 million in Q4 2025, from -$27.5 million in the prior quarter.
- In the past five years, EBIT ranged from a high of $71.1 million in Q2 2024 to a low of -$37.3 million in Q1 2024.
- A 5-year average of -$20.2 million and a median of -$25.4 million in 2022 frame the typical range for EBIT.
- Annual changes were most pronounced in 2024 — EBIT surged 375.54% — and 2025, when it slumped 136.89%.
- Tracing XFOR's EBIT over 5 years: stood at -$29.1 million in 2021, then grew by 11.97% to -$25.6 million in 2022, then grew by 1.48% to -$25.2 million in 2023, then sank by 41.73% to -$35.7 million in 2024, then soared by 33.64% to -$23.7 million in 2025.
- The last three EBIT figures came in at -$23.7 million (Q4 2025), -$27.5 million (Q3 2025), and -$26.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | X4 Pharmaceuticals | 533.17 Mn | 338.08 Mn | 7.19 Mn | -16.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.39 Mn |
| Dec 31, 2025 | -23.70 Mn |
| Sep 30, 2025 | -27.51 Mn |
| Jun 30, 2025 | -26.23 Mn |
| Mar 31, 2025 | -9.44 Mn |
| Dec 31, 2024 | -35.72 Mn |
| Sep 30, 2024 | -34.50 Mn |
| Jun 30, 2024 | 71.10 Mn |
| Mar 31, 2024 | -37.29 Mn |
| Dec 31, 2023 | -25.20 Mn |
| Sep 30, 2023 | -27.21 Mn |
| Jun 30, 2023 | -25.81 Mn |
| Mar 31, 2023 | -29.30 Mn |
| Dec 31, 2022 | -25.58 Mn |
| Sep 30, 2022 | -20.15 Mn |
| Jun 30, 2022 | -20.57 Mn |
| Mar 31, 2022 | -21.27 Mn |
| Dec 31, 2021 | -29.06 Mn |
| Sep 30, 2021 | -19.12 Mn |
| Jun 30, 2021 | -19.00 Mn |